FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:2796-2797 December 28, 2006 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear

(Contemporary Cardiology.) Edited by David A. Morrow. 620 pp., illustrated. Totowa, NJ, Humana Press, 2006. $175. ISBN 1-58829-526-5.

Since the 1950s, cardiac biomarkers have provided physicians with important information for managing the care of patients suspected of having had an acute myocardial infarction. In addition to clinical symptoms and typical electrocardiographic changes, elevated levels of cardiac biomarkers, particularly creatine kinase MB, have been considered essential in establishing the diagnosis of myocardial infarction. Over the past 15 years, other cardiac biomarkers have been identified, and they have proved useful in improving the diagnosis of a variety of cardiac diseases, in identifying persons at increased risk for a cardiovascular event, and in directing therapeutic decisions.

Given the many known cardiac . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.